{
  "nctId": "NCT03491553",
  "briefTitle": "Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B",
  "officialTitle": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Adult Subjects With Chronic Hepatitis B",
  "protocolDocument": {
    "nctId": "NCT03491553",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2019-08-27",
    "uploadDate": "2020-02-17T14:29",
    "size": 2665466,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03491553/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 48,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-04-06",
    "completionDate": "2020-08-10",
    "primaryCompletionDate": "2019-03-22",
    "firstSubmitDate": "2018-04-02",
    "firstPostDate": "2018-04-09"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria:\n\n* Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures\n* Adult males and non-pregnant, non-lactating females\n* Documented evidence of chronic HBV infection with detectable hepatitis B surface antigen (HBsAg) levels\n* On commercially available HBV OAV treatment(s) for at least 6 months with no change in regimen for 3 months prior to screening\n* HBV Deoxyribonucleic acid (DNA) ≤ 20 IU/mL for 6 or more months prior to screening\n* Screening Electrocardiogram (ECG) without clinically significant abnormalities\n\nKey Exclusion Criteria:\n\n* Extensive bridging fibrosis or cirrhosis\n* Adults meeting any of the protocol defined exclusionary laboratory parameters at screening:\n\n  * Alanine aminotransferase (ALT) \\> 3x Upper Limit of Normal (ULN)\n  * International normalized ratio (INR) \\> ULN unless the adult is stable on an anticoagulant regimen\n  * Albumin \\< 3.5 g/dL\n  * Direct bilirubin \\> 1.5x ULN\n  * Platelet Count \\< 100,000/uL\n  * Estimated creatinine clearance \\< 60 mL/min (using the Cockcroft-Gault method)\n* Co-infection with human immunodeficiency virus, hepatitis C virus or hepatitis D virus\n* Prior history of hepatocellular carcinoma (HCC) or screening alpha-fetoprotein ≥ 50 ng/mL without imaging\n* Diagnosis of autoimmune disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease, hemoglobinopathy, retinal disease, or are immunosuppressed.\n* Chronic liver disease of a non-HBV etiology, except for non-alcoholic fatty liver disease\n* Received solid organ or bone marrow transplant\n* Received prolonged therapy with immunomodulators or biologics within 3 months of screening\n* Use of another investigational agent within 90 days of screening, unless allowed by the Sponsor\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24",
        "timeFrame": "Week 24"
      }
    ],
    "secondary": [
      {
        "measure": "Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4",
        "timeFrame": "Week 4"
      },
      {
        "measure": "Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8",
        "timeFrame": "Week 8"
      },
      {
        "measure": "Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12",
        "timeFrame": "Week 12"
      },
      {
        "measure": "Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48",
        "timeFrame": "Week 48"
      },
      {
        "measure": "Change From Baseline in Serum qHBsAg at Week 4",
        "timeFrame": "Baseline, Week 4"
      },
      {
        "measure": "Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 8",
        "timeFrame": "Baseline, Week 8"
      },
      {
        "measure": "Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 12",
        "timeFrame": "Baseline, Week 12"
      },
      {
        "measure": "Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 24",
        "timeFrame": "Baseline, Week 24"
      },
      {
        "measure": "Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 48",
        "timeFrame": "Baseline, Week 48"
      },
      {
        "measure": "Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12",
        "description": "HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.",
        "timeFrame": "Week 12"
      },
      {
        "measure": "Percentage of Participants With HBsAg Loss at Week 24",
        "description": "HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Percentage of Participants With HBsAg Loss at Week 48",
        "description": "HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.",
        "timeFrame": "Week 48"
      },
      {
        "measure": "Percentage of Participants With HBeAg Loss and Seroconversion at Week 12",
        "description": "HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.",
        "timeFrame": "Week 12"
      },
      {
        "measure": "Percentage of Participants With HBeAg Loss and Seroconversion at Week 24",
        "description": "HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Percentage of Participants With HBeAg Loss and Seroconversion at Week 48",
        "description": "HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as hepatitis B e antibody (HBeAb) test changing from negative or missing at baseline to positive at a postbaseline visit.",
        "timeFrame": "Week 48"
      },
      {
        "measure": "Percentage of Participants With Virologic Breakthrough",
        "description": "Virologic breakthrough was defined as having two consecutive visits of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) ≥ 69 IU/mL.",
        "timeFrame": "Baseline up to Week 48"
      },
      {
        "measure": "Percentage of Participants With Drug Resistance Mutations",
        "description": "The criteria for a drug resistance mutation was having two consecutive visits of HBV DNA ≥ 69 IU/mL.",
        "timeFrame": "Baseline up to Week 48"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 17,
      "otherCount": 0,
      "totalCount": 18
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:23.841Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}